Oral Oncology
Volume 39, Issue 5 , Pages 483-490 , July 2003

Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype

  • Jong Y Park

      Affiliations

    • Divisions of Cancer Controls and Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Interdisciplinary Oncology, 12902 Magnolia Drive, Tampa, FL 33612, USA
    • Corresponding Author InformationCorresponding author. Fax: +1-813-632-1720
    • ,
  • Stimson P Schantz

      Affiliations

    • Department of Otolaryngology, The New York Eye and Ear Infirmary, 310 East 14th Street, New York, NY 10003, USA
    • ,
  • Philip Lazarus

      Affiliations

    • Divisions of Cancer Controls and Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Interdisciplinary Oncology, 12902 Magnolia Drive, Tampa, FL 33612, USA

Received 31 December 2002 ,Accepted 7 January 2003.

References 

  1. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 1995;4:589–594
  2. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997;6:733–743
  3. Lazarus P, Park JY. Metabolizing enzyme genotype and risk for upper aerodigestive tract cancer. Oral Oncol. 2000;36:421–431
  4. London SJ, Smart J, Daly AK. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer. 2000;28:147–155
  5. Park JY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie J, et al. Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics. 2000;10:123–131
  6. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase (genetic polymorphism and functional expression in vitro of amino acid variants). Hum Mol Genet. 1994;3:421–428
  7. Harrison DJ, Hubbard AL, MacMillan J, Wyllie AH, Smith CA. Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer. 1999;79:168–171
  8. Lin P, Wang SL, Wang HJ, Chen KW, Lee HS, Tsai KJ, et al. Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. Br J Cancer. 2000;82:852–857
  9. Wu X, Gwyn K, Amos CI, Makan N, Hong WK, Spitz MR. The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis. 2001;22:923–928
  10. Yin L, Pu Y, Liu TY, Tung YH, Chen KW, Lin P. Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer. 2001;33:133–141
  11. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res. 1998;58:5291–5293
  12. Zhao H, Spitz MR, Gwyn KM, Wu X. Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Mol Carcinog. 2002;33:99–104
  13. To-Figueras J, Gene M, Gomez-Catalan J, Pique E, Borrego N, Corbella J. Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1. Cancer Lett. 2001;173:155–162
  14. Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, et al. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog. 1996;17:160–162
  15. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res. 2000;60:534–536
  16. Janot F, Massaad L, Ribrag V, de Waziers I, Beaune PH, Luboinski B, et al. Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma. Carcinogenesis. 1993;14:1279–1283
  17. Park JY, Muscat J, Ren Q, Schantz SP, Harwick RD, Stern JC, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev. 1997;6:791–797
  18. Benhamou S, Benhamou E, Flamant R. Lung cancer risk associated with cigar and pipe smoking. Int J Cancer. 1986;37:825–829
  19. Ausubel FM, Brent R, Kingston R, Moore DD, Seidman JG, Smith JA. Current protocols in mol. biol., vol. 1. New York: John Wiley and Sons; 1988;
  20. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74:5463–5467
  21. SPSS . SPSS base 10.1 for windows, User's guide. Chicago: SPSS Inc; 2001;
  22. Phillips DH. Fifty years of benzo(a)pyrene. Nature. 1983;303:468–472
  23. Kihara M, Noda K, Okamoto N. Increased risk of lung cancer in Japanese smokers with class mu glutathione S-transferase gene deficiency. Cancer Lett. 1993;71:151–155
  24. Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis. 1994;15:415–418
  25. Kihara M, Kubota A, Furukawa M, Kimura H. GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers. Cancer Lett. 1997;112:257–262
  26. Worrall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, et al. Susceptibility and outcome in oral cancer (preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6). Pharmacogenetics. 1998;8:433–439

PII: S1368-8375(03)00008-3

doi: 10.1016/S1368-8375(03)00008-3

Oral Oncology
Volume 39, Issue 5 , Pages 483-490 , July 2003

Article Tools

* Image Usage & Resolution